JSR Life Sciences, LLC, announced that Similis Bio, its business unit focused on biosimilar development, have formed a partnership with Novel351k to co-develop three biosimilar programs that address a wide range of hard-to-treat diseases. Under the initial agreement, Similis will be responsible for cell line development, analytics, process development, and cGMP production, leading to pharmacokinetics/pharmacodynamic clinical trials. Novel351k will leverage its experience with regulatory and c...